SCHEMBL541660

SCHEMBL541660

CCOC(=O)N1CCc2[nH]c3ccc(C(=O)O)cc3c2C1

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.78
PABPC1 P11940 1/20 0.78
ATM Q13315 1/20 0.78
SMN1; SMN2 Q16637 1/20 0.78
POLB P06746 3/20 0.65
HSD17B10 Q99714 2/20 0.65
KDM4E B2RXH2 1/20 0.65
ALDH1A1 P00352 1/20 0.65
ALOX15 P16050 1/20 0.65
MAPK1 P28482 1/20 0.65
BAZ2B Q9UIF8 10/20 0.57
NPC1 O15118 2/20 0.56
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
RAB9A P51151 1/20 0.56
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2483701 0.91 LMNA (0.67) LMNAPABPC1ATMSMN1; SMN2POLB
SCHEMBL407460 0.87 LMNA (1.00) LMNAPABPC1ATMSMN1; SMN2POLB
SCHEMBL61901 0.87 LMNA (0.60) LMNAPABPC1ATMSMN1; SMN2POLB
SCHEMBL3312381 0.86 LMNA (0.57) LMNAPABPC1ATMSMN1; SMN2POLB
SCHEMBL10777655 0.85 SMN1; SMN2 (0.79) LMNAPABPC1ATMSMN1; SMN2POLB
SCHEMBL764099 0.85 LMNA (0.79) LMNAPABPC1ATMSMN1; SMN2POLB
SCHEMBL12868340 0.85 LMNA (0.79) LMNAPABPC1ATMSMN1; SMN2POLB
SCHEMBL12868564 0.84 LMNA (0.78) LMNAPABPC1ATMSMN1; SMN2POLB
SCHEMBL620615 0.83 LMNA (0.87) LMNAPABPC1ATMSMN1; SMN2POLB
SCHEMBL940424 0.82 LMNA (0.74) LMNAPABPC1ATMSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1509518-B1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC (US) 2012-02-08 EP disclosed
US-7176322-B2 Calcium receptor modulating agents AMGEN INC. (US) 2007-02-13 US disclosed
EP-1509518-A1 CALCIUM RECEPTOR MODULATING AGENTS Amgen, Inc. (US) 2005-03-02 EP disclosed
US-20040077619-A1 Calcium receptor modulating agents AMGEN INC. 2004-04-22 US disclosed
WO-2003099814-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN, INC. (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077619-A1 Calcium receptor modulating agents PTH1R, CASR, CALCR LMNA 3732/4885PABPC1 4292/4885ATM 4317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.